Luye Pharma GroupFRA:LUP +3.03%47 PB Ratio is 0.42 as of Jul. 03, 2026, which is 67% below its 10-year median of 1.28. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Luye Pharma Group ranks better than 93.05% on this metric.
The historical rank and industry rank for Luye Pharma Group's PB Ratio or its related term are showing as below:
FRA:LUP'
s PB Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.28 Max: 3.88
Current: 0.46
During the past 13 years, Luye Pharma Group's highest PB Ratio was 3.88. The lowest was 0.40. And the median was 1.28.
FRA:LUP's PB Ratio is ranked better than 93.05% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs FRA:LUP: 0.46
During the past 12 months, Luye Pharma Group's average Book Value Per Share Growth Rate was 10.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Luye Pharma Group was 88.30% per year. The lowest was -22.10% per year. And the median was 10.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Luye Pharma Group PB Ratio Related Terms
Luye Pharma Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Luye Pharma Group (FRA:LUP) has a PB Ratio of 0.42 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Luye Pharma Group and its competitors. This is 67% below median its historical median of 1.28. Over the past decade, Luye Pharma Group's PB Ratio has ranged from 0.40 to 3.88. According to the industry distribution chart, Luye Pharma Group ranks #64 out of 921 companies in the Drug Manufacturers industry, placing it in the top 6.9%.
Is Luye Pharma Group's PB Ratio too high?
Luye Pharma Group's current PB Ratio of 0.42 is 67% below median its 10-year median of 1.28. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 3.88. The Drug Manufacturers industry median PB Ratio is 1.91. Luye Pharma Group's value of 0.42 is 78% below this industry median. Based on the distribution chart, Luye Pharma Group ranks #64 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #64 out of 921 companies for PB Ratio. This places Luye Pharma Group in the top 7% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.91. Luye Pharma Group's value of 0.42 is 78% below this benchmark. Historically, Luye Pharma Group's own PB Ratio has ranged from 0.40 to 3.88 over the past decade. While the company's 10-year median is 1.28 vs. the industry median of 1.91, Luye Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current PB Ratio of 0.42 is 78% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current PB Ratio is 0.42, which is 67% below median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current PB Ratio is 0.42, which is 67% below median its 10-year median of 1.28 and 78% below the Drug Manufacturers industry median of 1.91. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current PB Ratio is 0.42 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
PB Ratio: 0.42 (67% below median its 10-year median of 1.28)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 78% below the Drug Manufacturers median (#64 of 921)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
